Le Lézard
Classified in: Science and technology
Subject: FDA

Oculo launches in the USA with FDA registration, HIPAA compliance and first US customer

SAN FRANCISCO and MELBOURNE, Australia, Sept. 18, 2019 /PRNewswire-PRWeb/ -- Oculo is pleased to announce its FDA registration and HIPAA compliance.

The Oculo® system is a web-enabled platform that addresses the global problems of data silos and disconnected clinical communication in healthcare. The cloud-based Oculo platform connects physicians regardless of location or the systems they use in their practices to facilitate the instant and secure transfer of patient data. Oculo powers the secure sharing of referrals, clinical imaging and test results between physicians.

Dr. Kate Taylor, CEO, Oculo, says "When we started Oculo in Australia four years ago, we knew the pain and clinical risks that occur when health data is trapped in disconnected silos. Quality care rests on continuity of communication. When patients have to act as carrier pigeons, vital information gets lost. This is a global problem. We are thrilled to be announcing our FDA registration and HIPAA compliance, meaning Oculo can connect clinical care for providers in the United States."

In Australia, over 80% of ophthalmologists and 65% of optometrists are using Oculo to communicate and share clinical imaging and data securely to facilitate better care for over 750,000 patients. In New Zealand, just 12 months post-launch, over 60% of eye care professionals are using Oculo.

Dr. Jade Schiffman, Neuro-Ophthalmology of Texas, is Oculo's founding customer in the USA. Dr. Schiffman and her colleagues will be using the Oculo platform integrated with Topcon's Harmony image management solution to streamline the flow of information in and out of her practice to her vibrant network of referring optometrists and ophthalmologists. Dr. Schiffman says "Oculo takes the images from Harmony with HIPAA security and compliance transports these images between providers now in Australia and New Zealand. The software is easy to operate and images are easy to select from Harmony as I understand and be sent (a process now that is hugely labor intensive, requiring extra staff to do all of this one image at a time).

"This ability itself is AMAZING because we have not found this yet! This takes the valuable time of our technicians who currently download each picture individually and upload it to the EMR individually, a much too time consuming process, or take pictures off the image management system and upload to EMR with much degradation of quality. So, this is the functionality we are excited to have."

The Oculo platform will be on show at Vision Expo West, Las Vegas, 19 - 21 September in collaboration with Topcon's Harmony image management solution.

About Oculo
Oculo is a secure, cloud-based clinical communications network designed to support better triage, telemedicine including teleophthalmology, and screening to connect clinicians around their patients, facilitating seamless co-managed care. The Oculo platform facilitates the secure, instant transfer of clinical imaging, referrals, and other clinical correspondence between healthcare professionals.

Oculo was founded by the Centre for Eye Research Australia and is based in Melbourne, Australia. Since launching in 2015, Oculo has grown a user base of over 3400 clinicians in Australia and New Zealand and has managed over 750,000 patients. Oculo is also the technology partner for KeepSight, a first-ever national diabetes eye care program funded by the Australian government in a public-private partnership.

Oculo is now working to connect clinicians around their patients around the world. In March 2019, Oculo partnered with Topcon Healthcare Solutions (THS), a global leader in eye care devices and image management.

For more information see https://www.oculo.co or contact media@oculo.com.au.



These press releases may also interest you

at 08:05
Axcella Health Inc. , a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced mechanistic data for AXA4010 that are being presented...

at 08:00
Genius Central, founded in October 1999, is celebrating 20 years in business providing essential components of the supply chain to the natural and specialty grocery industry. Processing over $2 billion in orders annually, the company's mission to...

at 08:00
Cellular Biomedicine Group Inc. ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies, announced early data from its ongoing investigator initiated trial ("IIT") at...

at 07:55
AstraZeneca today presented results from the interim analysis of the Phase III ELEVATE TN trial, showing that CALQUENCE® (acalabrutinib) combined with obinutuzumab or as monotherapy significantly improved progression-free survival (PFS) compared to...

at 07:33
AbbVie , a research-based global biopharmaceutical company, today announced results from an extended follow-up analysis of the Phase 3 E1912 clinical study ? designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by...

at 07:30
AbbVie , a research-based global biopharmaceutical company, today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial,1 evaluating IMBRUVICA® (ibrutinib) in combination with VENCLEXTA®/VENCLYXTO® (venetoclax) in previously...

News published on 18 september 2019 at 11:00 and distributed by: